Janus Henderson Global Life Sciences Fund Class C
JFNCX
NASDAQ- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management - Global
- Address
- 151 Detroit Street Denver CO United States of America 80206
- IPO Date
- Jul 6, 2009
- CIK
- 0000277751
- Website
- janushenderson.com
- Similar Companies
- Business
- Janus Henderson Global Life Sciences Fund Class C (JFNCX) is an open-ended investment company that seeks long-term growth of capital by investing primarily in equity securities of companies worldwide positioned to benefit from innovation in the life sciences and healthcare sectors, including those addressing unmet medical needs or improving healthcare system efficiency. The fund employs a diversified, bottom-up approach across market capitalizations and geographies, with core holdings in biotechnology, pharmaceuticals, medical devices, and healthcare services; top holdings include Eli Lilly and Co (9.78%), UnitedHealth Group Inc (5.36%), AstraZeneca PLC (4.07%), Boston Scientific Corp (3.20%), and Sanofi SA (3.18%), representing 25.59% of the portfolio. Launched on July 6, 2009, and domiciled in the United States with daily pricing in USD, the fund is managed by Andy Acker (since May 1, 2007) and Daniel Lyons (since January 31, 2023), supported by a team of healthcare specialists with over 95 years of combined experience; it maintains approximately 78% U.S. stocks, 21% non-U.S. stocks, and nearly 99% allocation to the healthcare sector, targeting institutional and retail investors through a minimum initial investment of $2,500 and a net expense ratio of 1.76%. Geographically, the portfolio spans the United States (78%), Europe ex-Euro (8%), the United Kingdom (6%), Eurozone (3%), and emerging Asia (3%). Recent developments include strong Q3 2025 performance with an 8.26% return, outperforming the MSCI World Health Care Index by over 5 percentage points, driven by holdings like Argenx and Avidity Biosciences; SFDR-related updates to the broader Global Life Sciences strategy effective November 21, 2025; and Janus Henderson's expansion into private markets via the MENA Private Credit Fund IV ($125.5 million first close in October 2025) and Privacore partnerships with CNO Financial Group and Victory Park Capital. The firm, formerly Janus Capital Management until its 2017 rebranding following the merger with Henderson Investors, continues to leverage its healthcare expertise amid growing demand from aging populations and R&D advancements.